Sugi Predict

Sugi Predict / Compounds / SCHEMBL2353757

SCHEMBL2353757

SCHEMBL2353757

Cc1ccc(C(=O)c2ccc[nH]2)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.58
▸ LMNA P02545 1/20 0.58
▸ NPC1 O15118 3/20 0.54
▸ RAB9A P51151 3/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ SRD5A2 P31213 1/20 0.50
▸ AKR1C3 P42330 1/20 0.47
▸ CES2 O00748 2/20 0.46
▸ CES1 P23141 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ TSHR P16473 1/20 0.43
▸ CYP2D6 P10635 1/20 0.42
▸ CCND3 P30281 1/20 0.42
▸ CDK6 Q00534 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL5593607 0.94 ALDH1A1 (0.52) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL13328057 0.85 TPMT (0.47) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL9650611 0.82 PARP1 (0.50) SMN1; SMN2KDM4EL3MBTL1MEN1KMT2A
SCHEMBL13328043 0.82 RAB9A (0.45) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL1897467 0.82 MAPT (0.56) LMNANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1074961 0.81 ALDH1A1 (0.56) ALDH1A1RAB9ASMN1; SMN2SRD5A2AKR1C3
SCHEMBL15979652 0.80 RAB9A (0.71) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL371069 0.80 TSHR (0.54) LMNANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3173685 0.80 HPGD (0.46) LMNANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3164756 0.80 LMNA (0.54) LMNANPC1RAB9ASMN1; SMN2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105958011-B Nonaqueous electrolyte secondary battery and positive electrode sheet for same 日东电工株式会社 2020-07-03 — — CN disclosed
CN-110325512-A The method for being used to prepare chiral pyrrolidine -2- base carbinol derivatives 豪夫迈·罗氏有限公司 2019-10-11 — — CN disclosed
US-20180143185-A1 CHEMICAL FLUORESCENT PROBES FOR DETECTING BIOFILMS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2018-05-24 — — US disclosed
EP-1647546-B1 NOVEL HETEROARYL DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2012-05-02 — — EP disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 — — US disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 — — US disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 — — US disclosed
EP-2351563-A1 AGENT FOR TREATMENT OF DIABETES Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-08-03 — — EP disclosed
EP-2351563-A1 AGENT FOR TREATMENT OF DIABETES Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-08-03 — — EP disclosed
US-20100286144-A1 HETEROARYL DERIVATIVES TAKAHASHI YOKO 2010-11-11 — — US disclosed
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 — — US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 — — EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 — — US disclosed
US-20040162331-A1 Pyrrole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-08-19 — — US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 — — US disclosed
EP-1386913-A1 PYRROLE DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-02-04 — — EP disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 — — US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 — — EP disclosed
US-5041442-A Antiulcer agents SYNTEX (U.S.A.) INC. (US) 1991-08-20 — — US disclosed
EP-0011279-B1 PROCESS FOR THE PREPARATION OF AROMATICALLY SUBSTITUTED ACETIC ACIDS SAGAMI CHEMICAL RESEARCH CENTER (JP) 1982-05-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 ALDH1A1 476/4885LMNA 4536/4885NPC1 1550/4885
US-20180143185-A1 CHEMICAL FLUORESCENT PROBES FOR DETECTING BIOFILMS GMPS, FAP, FDPS ALDH1A1 1654/4885LMNA 1586/4885NPC1 3662/4885
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES SLC5A1, GLP1R, SLC5A2 ALDH1A1 291/4885LMNA 4388/4885NPC1 1605/4885
US-20100286144-A1 HETEROARYL DERIVATIVES GPR119, SLC2A1, SLC2A4 ALDH1A1 631/4885LMNA 1680/4885NPC1 115/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 ALDH1A1 603/4885LMNA 4453/4885NPC1 1814/4885
US-20040162331-A1 Pyrrole derivative SLC5A1, GLP1R, SLC5A2 ALDH1A1 548/4885LMNA 4783/4885NPC1 2030/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 ALDH1A1 530/4885LMNA 4564/4885NPC1 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.